These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 28755323)
1. Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis. Fogli A; Demattei MV; Corset L; Vaurs-Barrière C; Chautard E; Biau J; Kémény JL; Godfraind C; Pereira B; Khalil T; Grandin N; Arnaud P; Charbonneau M; Verrelle P J Neurooncol; 2017 Nov; 135(2):381-390. PubMed ID: 28755323 [TBL] [Abstract][Full Text] [Related]
2. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas. Grandin N; Pereira B; Cohen C; Billard P; Dehais C; Carpentier C; Idbaih A; Bielle F; Ducray F; Figarella-Branger D; Delattre JY; Sanson M; Lomonte P; Poncet D; Verrelle P; Charbonneau M; Acta Neuropathol Commun; 2019 Nov; 7(1):175. PubMed ID: 31706351 [TBL] [Abstract][Full Text] [Related]
3. Molecular Characteristics of Thalamic Gliomas in Adults. Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385 [TBL] [Abstract][Full Text] [Related]
4. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma. Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335 [TBL] [Abstract][Full Text] [Related]
5. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234 [TBL] [Abstract][Full Text] [Related]
6. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas. Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898 [TBL] [Abstract][Full Text] [Related]
8. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas. Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161 [TBL] [Abstract][Full Text] [Related]
9. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas. Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718 [TBL] [Abstract][Full Text] [Related]
11. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging. Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261 [TBL] [Abstract][Full Text] [Related]
12. Tumor location and patient age predict biological signatures of high-grade gliomas. Altieri R; Zenga F; Ducati A; Melcarne A; Cofano F; Mammi M; Di Perna G; Savastano R; Garbossa D Neurosurg Rev; 2018 Apr; 41(2):599-604. PubMed ID: 28856492 [TBL] [Abstract][Full Text] [Related]
13. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Lötsch D; Ghanim B; Laaber M; Wurm G; Weis S; Lenz S; Webersinke G; Pichler J; Berger W; Spiegl-Kreinecker S Neuro Oncol; 2013 Apr; 15(4):423-32. PubMed ID: 23393205 [TBL] [Abstract][Full Text] [Related]
15. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta. Novakovic B; Napier CE; Vryer R; Dimitriadis E; Manuelpillai U; Sharkey A; Craig JM; Reddel RR; Saffery R Mol Hum Reprod; 2016 Nov; 22(11):791-799. PubMed ID: 27604461 [TBL] [Abstract][Full Text] [Related]
16. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas. Siegal T Adv Tech Stand Neurosurg; 2016; (43):91-108. PubMed ID: 26508407 [TBL] [Abstract][Full Text] [Related]
17. Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas. Haberler C; Wöhrer A Clin Neuropathol; 2014; 33(2):108-11. PubMed ID: 24559763 [TBL] [Abstract][Full Text] [Related]
18. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324 [TBL] [Abstract][Full Text] [Related]
19. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma. Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668 [TBL] [Abstract][Full Text] [Related]
20. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Jiao Y; Killela PJ; Reitman ZJ; Rasheed AB; Heaphy CM; de Wilde RF; Rodriguez FJ; Rosemberg S; Oba-Shinjo SM; Nagahashi Marie SK; Bettegowda C; Agrawal N; Lipp E; Pirozzi C; Lopez G; He Y; Friedman H; Friedman AH; Riggins GJ; Holdhoff M; Burger P; McLendon R; Bigner DD; Vogelstein B; Meeker AK; Kinzler KW; Papadopoulos N; Diaz LA; Yan H Oncotarget; 2012 Jul; 3(7):709-22. PubMed ID: 22869205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]